Saturday 17 October 2026
Export PLRX’s income statement to Excel — free account
Pliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.
0.90
0.07
−7.22%
Follow PLRX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 1 | 3 | 4 | — | — |
P/E ratio |
— | — | 1.39 | 6.66 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
— | — | — | 23.59 | 11.37 | 11.64 | 15.11 | — | — |
P/S ratio |
— | — | 0.00 | 11.60 | 63.91 | 82.43 | 209.79 | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | 16.27 | 27.79 | 9.01 | 9.16 | 13.40 | — | — |
Beneish M-Score |
— | — | — | (2.56) | 2.82 | 8.37 | — | — | — |
P/Operating CF |
— | — | (3.17) | (29.42) | (24.36) | (25.55) | (42.01) | — | — |
P/B ratio |
— | — | 0.00 | 1.71 | 2.43 | 2.55 | 2.23 | — | — |
Price to Tangible BV |
— | — | 0.00 | 1.71 | 2.43 | 2.55 | 2.23 | — | — |
EV/Sales |
— | — | 0.00 | 4.98 | 38.12 | 49.26 | 113.47 | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | 21.63 | (5.58) | (3.83) | (5.04) | (4.90) | — | — |
EV/FCF |
— | — | 17.69 | (5.36) | (3.73) | (4.95) | (4.86) | — | — |
Quick Ratio |
— | 12.09 | 13.48 | 24.68 | 12.04 | 13.94 | 17.33 | 10.71 | 11.67 |
Current Ratio |
— | 12.14 | 13.69 | 25.07 | 12.44 | 14.23 | 17.72 | 10.91 | 12.00 |
Net Debt/EBITDA |
— | 2.01 | 870.96 | 6.86 | 2.06 | 2.53 | 2.59 | 1.45 | 1.27 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 2.41% | 2.83% | 1.96% | 7.61% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.02 | 0.10 | 0.00 |
Asset Turnover |
— | 0.00 | 0.61 | 0.20 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.81 | 0.40 | 0.90 | 0.78 | 0.77 | 0.72 | 0.74 | 0.86 |
Capex/Depreciation |
— | (3.49) | (0.87) | (1.17) | (0.70) | (103.53) | 0.29 | (0.83) | (0.04) |
Interest Coverage |
— | (44.93) | (1.51) | (87.12) | — | (160.81) | (145.34) | (75.52) | (61.11) |
| — | 47.58% | 9.28% | (40.17%) | (40.35%) | (48.13%) | (41.00%) | (54.09%) | (61.55%) | |
| — | (105.67%) | (7.39%) | (20.04%) | (37.64%) | (43.13%) | (37.40%) | (46.27%) | (48.01%) | |
ROIC |
— | 0.00% | (10.68%) | (422.05%) | (1,609.28%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (57.71%) | (6.36%) | (14.65%) | (49.32%) | (38.43%) | (33.57%) | (62.86%) | (81.60%) |
Average Days of Receivables |
— | 0.00 | 47.25 | 81.72 | 100.31 | 77.86 | 0.00 | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 83.00% | 158.29% | 1,024.15% | 1,000.89% | 8,088.42% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 19.16% | 41.30% | 363.95% | 412.48% | 3,666.33% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 3.21% | 9.31% | 137.84% | 233.33% | 2,815.38% | 0.00% | 0.00% |
Graham Net Nets |
— | — | 4.10 | 0.57 | 0.39 | 0.38 | 0.44 | — | — |
Graham Number |
— | — | 20.27 | 31.90 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
— | — | 72.15% | 15.01% | (20.07%) | (15.63%) | (15.37%) | — | — |
Free Cash Flow Yield |
— | — | (14.13%) | (8.00%) | (15.99%) | (12.07%) | (11.12%) | — | — |
Revenue per Share |
— | 0.00 | 35.14 | 1.96 | 0.21 | 0.23 | 0.03 | 0.00 | 0.00 |
Operating CF per Share |
— | (24.31) | (1.69) | (1.75) | (2.10) | (2.25) | (1.98) | (2.57) | (2.09) |
Capex per Share |
— | (1.99) | (0.59) | (0.07) | (0.05) | (0.04) | (0.02) | (0.06) | 0.00 |
Free Cash Flow per Share |
— | (26.30) | (2.29) | (1.82) | (2.16) | (2.29) | (2.00) | (2.63) | (2.09) |
Cash per Share |
— | 52.29 | 63.31 | 12.97 | 5.60 | 7.88 | 8.42 | 5.88 | 3.11 |
Shareholders Equity per Share |
— | 52.02 | 67.75 | 13.26 | 5.55 | 7.46 | 8.07 | 5.02 | 2.95 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 52.02 | 67.75 | 13.26 | 5.55 | 7.46 | 8.07 | 5.02 | 2.95 |
Free Cash Flow |
— | (30.65) | (3.71) | (38.80) | (77.40) | (96.39) | (117.28) | (159.35) | (128.55) |
Working Capital |
— | 56.65 | 103.73 | 279.16 | 192.61 | 316.40 | 476.98 | 329.05 | 180.08 |
Capital Expenditures |
— | (2.32) | (0.96) | (1.53) | (1.95) | (1.76) | (0.92) | (3.85) | (0.22) |
Net Current Asset Value |
— | 55.84 | 102.82 | 278.29 | 187.29 | 303.04 | 466.92 | 269.40 | 152.43 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
— | 0.00 | 0.02 | 0.04 | 0.26 | 0.18 | 0.58 | 0.00 | 0.00 |
Price to Operating Income |
— | — | 1.68 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.16 | 0.27 | 0.30 | 0.61 | 0.00 | (0.88) | 0.84 | 1.92 |
Cash ROIC |
— | (25.21%) | (1.75%) | (6.93%) | (19.11%) | (14.73%) | (11.99%) | (23.09%) | (34.54%) |
Accounts Receivable Turnover |
— | 0.00 | 14.47 | 4.99 | 1.32 | 4.67 | 0.00 | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 3.94 | 3.94 | 8.37 | 5.72 | 2.07 | — | — | — |
Average Payables |
— | 1.91 | 1.91 | 1.64 | 2.50 | 2.28 | 3.06 | 5.25 | 3.22 |
Average Assets |
— | 33.26 | 92.80 | 207.30 | 258.37 | 285.91 | 431.38 | 454.55 | 311.09 |
Average Common Equity |
— | (73.88) | (73.88) | 103.38 | 241.06 | 256.20 | 393.46 | 388.83 | 242.64 |
Columns are period end dates